Immune Checkpoint Inhibitors Market is expected to witness a robust CAGR of 11.8% And estimated to surpass US$ 40,882.6 Million by 2028 | Bristol-Myers Squibb Company, Merck & Co., Inc

Demand for immune checkpoint inhibitors is predicted to extend because of the increasing prevalence of cancer. Also, innovative drug launches with strong pipelines are likely to spice up the world immune checkpoint inhibitor market within the estimated period. Major manufacturers are investing in R&D to develop immune-checkpoint therapies by understanding the functions of tumors and ways to combat them.

Request Here For PDF Brochure With Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/2560

Manufacturers are specializing in upgrading the available immune checkpoint inhibitors yet as developing new immune checkpoint inhibitors for the treatment of cancer. as an example, AstraZeneca’s Durvalumab (Imfinzi) was approved as an immune checkpoint inhibitor in 2017, blocking the interaction of PD-1 and PD-L1 with CD80. In December 2017, Bristol-Myers Squibb was approved for Nivolumab (Opadivo) within the adjuvant treatment of melanoma. In March 2017, Avelumab (Bavencio), jointly developed by EMD Serono and Pfizer, Inc., was approved by the US Food and Drug Administration (FDA) for the treatment of metastatic Merkel cell carcinoma. In 2017, the USFDA immediately approved the immunotherapy product-TECENTRIQ (atezolizumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC).

Research and development by leading in addition as small and medium-sized players within the Immune Checkpoint Inhibitors market are likely to support the expansion of the world Immune Checkpoint Inhibitor market. for instance, Oncolytics Biotech, Inc. announced a pursuit collaboration with the Keck School of medication of the University of Southern California (USC) in May 2018 to develop a combined therapy for Reolycin (a product of Oncolytics Biotech), Keytruda, Velcade, and dexamethasone myeloma. Moreover, in January 2018, Merck & Co. Keytruda, developed by, slowed the progression of carcinoma in Phase 2 trials. Immuno-oncology combination therapies are being researched for various cancer indications.

In January 2018, the USFDA rated Lenvima-Keytruda Combo Breakthrough Therapy for Advanced Kidney Cancer. Furthermore, Opdivo-Yervoy combination therapy in February 2018 showed delayed disease progression in patients with advanced non-small-cell carcinoma. Furthermore, Genentech Combination Therapy Tecentriq and Avastin delayed the expansion of kidney cancer in December 2017 in clinical test trials. AstraZeneca Plc’s Imfinzi (Durvalumab) showed progression to delayed non-small cell carcinoma in clinical test trials in November 2017.

Get Sample Report With Latest Covid19 Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/2560

Global Immune Checkpoint Inhibitors Market: Key Takeaways

• The size of the global immune checkpoint inhibitors market was estimated at US$ 10,543.8 million in 2017, and during the estimated period (2018–2026) it likely to witness a robust CAGR of 11.8%. It is credited with the presence of several leading manufacturers focusing on introducing innovative treatments through extensive R&D, like Pfizer Inc, Novartis and Bristol Myers Squibb.
• Biopharmaceutical companies are developing a robust pipeline of immune-checkpoint inhibitor combination therapy due to their growing demand. U.S. The Food and Drug Administration (FDA) has approved a number of immune checkpoint inhibitors, including Yervoy (Anti-CTLA-4), Opdivo and Keytruda (anti-PD1) and Tecentriq (anti-PD-L1).
• Due to the positive results of the immuno-checkpoint inhibitor combination therapy in clinical trials, market conditions are likely to change over the estimated period.
• Research partnerships and collaborations to develop new drugs by different players in the market are supporting the growth of the market, as competitors strive to gain a competitive edge in the market.

Global Immune Checkpoint Inhibitors Market: Competitive Landscape

Key players performing in the global immune checkpoint inhibitors market are Pfizer Inc., Ono Pharmaceutical Co. Ltd., NewLink Genetics Corporation, Immutep Ltd., ImmunOs Therapeutics AG, Novartis International AG, AstraZeneca Plc., F. Hoffmann-La Roche AG, Merck & Co. Inc., and Bristol-Myers Squibb Company.

Direct Purchase This Report with Access of full Information @ https://www.coherentmarketinsights.com/insight/buy-now/2560

Reasons to Purchase This Report

• Current and future of Immune Checkpoint Inhibitors Market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players

Table of Contents

1. Research Objective and assumption
   • Research Objectives
   • Assumptions
   • Abbreviations
2. Market Purview
   • Report Description
     • Market Definition and Scope
   • Executive Summary
     • Market Snippet, By Drug Class
     • Market Snippet, By Application
     • Market Snippet, By Region
   • Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Drivers
     • Restraints
     • Market Opportunities
   • Impact Analysis
   • Epidemiology
   • Collaborations & Partnerships
   • Major FDA Approvals & Product Launch Scenario
   • Pipeline Analysis
   • Regulatory Scenario
   • Reimbursement Scenario
   • PEST Analysis
   • Porter’s Five Forces Analysis
4. Global Immune Checkpoint Inhibitors Market, By Drug Class, 2018–2026 (US$ Mn)
   • Introduction
     • Market Share Analysis, 2018 and 2026 (%)
     • Y-o-Y Growth Analysis, 2017–2026
     • Segment Trends
   • Programmed Death Receptor-1 (PD-1) Inhibitors
     • Pembrolizumab (Keytruda)
     • Nivolumab (Opdivo)
     • Cemiplimab (Libtayo)
     • Others
   • Programmed Death-Ligand 1 (PD-L1) Inhibitors
     • Atezolizumab (Tecentriq)
     • Avelumab (Bavencio)
     • Durvalumab (Imfinzi)
   • CTL-4 Checkpoint Inhibitor
     • Ipilimumab (Yervoy)
   • Indoleamine-2,3-dioxygenase (IDO) Inhibitors
   • Lymphocyte-Activation Gene 3 Inhibitors
5. Global Immune Checkpoint Inhibitors Market, By Application, 2018–2026 (US$ Mn)
   • Introduction
     • Market Share Analysis, 2018 and 2026 (%)
     • Y-o-Y Growth Analysis, 2017–2026
     • Segment Trends
   • Lung Cancer
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
   • Head & Neck Cancer
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
   • Skin Cancer (Melanoma and Merkel Cell Carcinoma)
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
   • Blood Cancer (Lymphoma)
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
   • Bladder Cancer (Urothelial Carcinoma)
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
   • Renal/Kidney Cancer
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
   • Colorectal Cancer
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
   • Breast Cancer
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
   • Others
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
6. Global Immune Checkpoint Inhibitors Market, By Distribution Channel, 2018–2026 (US$ Mn)
   • Introduction
     • Market Share Analysis, 2018 and 2026 (%)
     • Y-o-Y Growth Analysis, 2017–2026
     • Segment Trends
   • Hospital Pharmacies
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
   • Retail Pharmacies
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
   • Online Pharmacies
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
7. Global Immune Checkpoint Inhibitors Market, By Regions, 2018–2026 (US$ Mn)
   • Introduction
     • Market Share Analysis, By Region, 2018 and 2026 (%)
     • Y-o-Y Growth Analysis, For Regions, 2017–2026
   • North America
     • Market Size and Forecast, By Drug Class, 2018–2026 (US$ Mn)
     • Market Size and Forecast, By Application, 2018–2026 (US$ Mn)
     • Market Size and Forecast, By Distribution Channel, 2018–2026 (US$ Mn)
     • Market Size and Forecast, By Country, 2018–2026 (US$ Mn)
       • U.S.
       • Canada
   • Europe
     • U.K.
     • Germany
     • Italy
     • France
     • Spain
     • Russia
     • Rest of Europe
   • Asia Pacific
     • China
     • India
     • Japan
     • ASEAN
     • Australia
     • South Korea
     • Rest of APAC
   • Latin America
     • Brazil
     • Mexico
     • Argentina
     • Rest of LATAM
   • Middle East
     • GCC
     • Israel
     • Rest of Middle East
   • Africa
     • North Africa
     • Central Africa
     • South Africa